Xenon Pharmaceuticals Inc. (XENE) Files DEF 14A on April 22
Published on 4/22/2026

AI Summary
Xenon Pharmaceuticals Inc. (XENE) submitted its DEF 14A filing on April 22. This document includes important shareholder information and is a required filing for upcoming meetings. Specific details regarding executive compensation, board nominees, and shareholder proposals are typically outlined in such filings. The filing ensures compliance with SEC regulations and aids in transparency for investors.
Related News

IPO
SpaceX (SPCX) Sets IPO Price at $135, Valuing Company at $1.75 Trillion
Jun 6

Regulation
Alvotech (ALVO) Receives FDA Form 483 from June 2026 Inspection
Jun 6

Markets
CAKE Director Sells 2,490 Shares for $162,000 on June 2, 2026
Jun 6

Regulation
Trump Pardons Former Congressman Convicted of Securities Fraud
Jun 6